PHCCC: Difference between revisions

{{drugbox

| verifiedrevid = 407876215

| IUPAC_name = (-)-N-Phenyl-7-(hydroxyimino)cyclopropa[b]chromen-1a-carboxamide

| image = PHCCC_structure.png

| width = 200

| CAS_number =

| ATC_prefix =

| ATC_suffix =

| PubChem = 3579925

| DrugBank =

| C=17|H=14|N=2|O=3

| molecular_weight = 294.304 g/mol

| smiles = c4ccccc4NC(=O)C1(CC1C2=NO)Oc3ccccc23

| bioavailability =

| protein_bound =

| metabolism =

| elimination_half-life =

| excretion =

| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->

| pregnancy_US = <!-- A / B / C / D / X -->

| pregnancy_category=

| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->

| legal_CA = <!-- / Schedule I, II, III, IV, V, VI, VII, VIII -->

| legal_UK = <!-- GSL / P / POM / CD / Class A, B, C -->

| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->

| legal_status =

| routes_of_administration =

'''PHCCC''' is a research drug which acts as a [[glutamate receptor]] ligand, particularly being a [[positive allosteric modulator]] at the [[Metabotropic glutamate receptor 4|mGluR₄]] subtype,<ref name="pmid14573382">{{cite journal |author=Maj M, Bruno V, Dragic Z, Yamamoto R, Battaglia G, Inderbitzin W, Stoehr N, Stein T, Gasparini F, Vranesic I, Kuhn R, Nicoletti F, Flor PJ |title=(-)-PHCCC, a positive allosteric modulator of mGluR4: characterization, mechanism of action, and neuroprotection |journal=Neuropharmacology |volume=45 |issue=7 |pages=895–906 |year=2003 |month=December |pmid=14573382 |doi= 10.1016/S0028-3908(03)00271-5|url=}}</ref> as well as an agonist at [[Metabotropic glutamate receptor 6|mGluR₆]].<ref name="pmid18593581">{{cite journal |author=Beqollari D, Kammermeier PJ |title=The mGlu(4) receptor allosteric modulator N-phenyl-7-(hydroxyimino)cyclopropa[b]chromen-1a-carboxamide acts as a direct agonist at mGlu(6) receptors |journal=European Journal of Pharmacology |volume=589 |issue=1-3 |pages=49–52 |year=2008 |month=July |pmid=18593581 |doi=10.1016/j.ejphar.2008.06.054 |url=}}</ref> It has anxiolytic effects in animal studies.<ref name="pmid15363989">{{cite journal |author=Stachowicz K, Kłak K, Kłodzińska A, Chojnacka-Wojcik E, Pilc A |title=Anxiolytic-like effects of PHCCC, an allosteric modulator of mGlu4 receptors, in rats |journal=European Journal of Pharmacology |volume=498 |issue=1-3 |pages=153–6 |year=2004 |month=September |pmid=15363989 |doi=10.1016/j.ejphar.2004.07.001 |url=}}</ref> PHCCC and similar drugs have been suggested as novel treatments for [[Parkinson's disease]].<ref name="pmid18664603">{{cite journal |author=Niswender CM, Johnson KA, Weaver CD, Jones CK, Xiang Z, Luo Q, Rodriguez AL, Marlo JE, de Paulis T, Thompson AD, Days EL, Nalywajko T, Austin CA, Williams MB, Ayala JE, Williams R, Lindsley CW, Conn PJ |title=Discovery, characterization, and antiparkinsonian effect of novel positive allosteric modulators of metabotropic glutamate receptor 4 |journal=Molecular Pharmacology |volume=74 |issue=5 |pages=1345–58 |year=2008 |month=November |pmid=18664603 |doi=10.1124/mol.108.049551 |url= |pmc=2574552}}</ref>

== References ==

{{Reflist}}

{{Glutamate_receptor_ligands}}

[[Category:Drugs]]

{{pharm-stub}}